A Form FDA 483 and an FDA Warning Letter are not the same document. A 483 lists the investigator's observations at the end of an inspection and is not a final agency determination. A Warning Letter comes later, if FDA decides the violations are of regulatory significance, and is published on fda.gov. Searchers often mix the two up, but the status, timing and response expected are different.
The context has also changed. On 2 February 2026, the Quality Management System Regulation (QMSR) took effect: 21 CFR Part 820 now incorporates ISO 13485:2016 by reference, and FDA stopped using QSIT and began inspecting device manufacturers under Compliance Program 7382.850. The 15-business-day window for 483 responses dates from a Federal Register notice of 11 August 2009, 74 FR 40211. A 483 issued today cites a regulation that runs through ISO 13485, and how a firm reads it shapes what comes next.
This article explains what each document is, how FDA classifies inspections, how to respond, and how a Warning Letter is closed out.
What a Form 483 is
According to FDA's Form 483 FAQ, a Form 483 is issued to firm management at the conclusion of an inspection when an investigator has observed conditions that, in their judgement, may constitute violations of the FD&C Act and related Acts. Each observation is read and discussed with the company's senior management.
Three points define its status:
It is not a final determination. The FAQ states that the 483 does not constitute a final Agency determination of whether any condition is in violation. The form's own preprinted wording, as quoted in 74 FR 40211, says the observations "are inspectional observations; and do not represent a final agency determination regarding your compliance".
It is not exhaustive. FDA's FAQ confirms that the 483 is not intended to be an all-inclusive list of every possible deviation. Conditions that were not written up can still be relevant.
It is one input among several. FDA considers the 483 together with the Establishment Inspection Report (EIR), all evidence collected during the inspection and any responses made by the company before deciding on further action.
For device manufacturers, the underlying requirement carries the weight. Under 21 CFR 820.10(e), failure to comply with any applicable requirement of Part 820 renders a device adulterated.
How FDA classifies an inspection
After the inspection, FDA assigns one of three classifications, defined in its Inspection Classification Database:
| Classification | FDA definition |
|---|---|
| NAI: No Action Indicated | The facility is in an acceptable state of compliance |
| VAI: Voluntary Action Indicated | Objectionable conditions were found, but FDA has determined the facility can voluntarily correct them and will not recommend any action |
| OAI: Official Action Indicated | The facility is in an unacceptable state of compliance |
FDA states that the final classification is usually sent to the firm in a letter within 45 to 90 days from the close of the inspection.
Responding to a 483
A written response is not legally required, but FDA's FAQ encourages companies to respond in writing with their corrective action plan. The Classification Database page also encourages firms to submit their corrective action plan with supporting documentation.
The timing matters. Under 74 FR 40211:
for responses received within 15 business days of the 483, FDA plans to conduct a detailed review before deciding whether to issue a Warning Letter;
FDA will not ordinarily delay a Warning Letter in order to review a response received after that period;
FDA does not plan to routinely comment on the adequacy of the firm's corrective actions in a Warning Letter; and
FDA may issue a Warning Letter at any time, and ongoing or promised corrective actions generally do not prevent one.
In our view, a 483 is an early signal, not a verdict, and a timely, complete response is the firm's main chance to be heard before FDA decides on a Warning Letter. A credible response separates containment, root cause, scope, systemic correction, responsible owner, due date and effectiveness check, and attaches evidence rather than promises.
Answer the system, not only the observation. If a complaint record was incomplete, FDA will expect the firm to show it has reviewed other complaint records, not just the one cited. With ISO 13485 incorporated through 820.10, software teams' design and complaint records will be read against ISO 13485 clauses. Our article on the QMSR and ISO 13485:2016 explains how the regulation is structured.
What a Warning Letter is
FDA's Regulatory Procedures Manual, Chapter 4 (Revision 12, July 2024) describes Warning Letters as follows:
they are issued only for violations of regulatory significance;
they are FDA's principal means of achieving prompt voluntary compliance;
they are informal and advisory, and official but not final agency action;
an inspection is classified OAI whenever a Warning Letter is issued;
a Warning Letter is not a prerequisite to taking enforcement action; and
FDA usually requests a written response within 15 working days of receipt.
FDA publishes Warning Letters in a searchable database on its Warning Letters page. A 483 response is a correction plan for observed conditions. A Warning Letter response has to address an agency view that the violations are significant, and it becomes part of a public record.
Form 483 and Warning Letter compared
| Aspect | Form 483 | Warning Letter |
|---|---|---|
| When issued | At the conclusion of an inspection, when observations are made | When FDA decides violations are of regulatory significance |
| Who decides | The investigator, who discusses the observations with management | FDA, following agency review |
| Status | Not a final Agency determination | Informal and advisory; official but not final agency action |
| Response window | 15 business days for a detailed review before a Warning Letter decision | Usually 15 working days from receipt |
| Public posting | Not stated | Published in FDA's Warning Letters database |
| What follows | Classification as NAI, VAI or OAI, usually within 45 to 90 days | OAI classification; possible further enforcement; close-out once corrections are verified |
Sources: FDA Form 483 FAQ; 74 FR 40211; Inspection Classification Database; RPM Chapter 4; FDA Warning Letters and Close-Out Letters pages.
Close-out letters
FDA's close-out letter process applies to Warning Letters issued on or after 1 September 2009. A close-out letter is issued only after the corrections have actually been made and verified by FDA, usually through a follow-up inspection. If the violations are by their nature not correctable, no close-out letter is issued.
A close-out letter does not end FDA's interest. FDA notes that future inspections may further assess the adequacy and sustainability of the corrections.
A hypothetical example
Hypothetical example: a Dutch SaMD manufacturer with a US-marketed software device is inspected after 2 February 2026. At the close of the inspection, the investigator issues a 483 with two observations:
complaint records without a documented evaluation or MDR reportability decision (820.35(a), ISO 13485 clause 8.2.2 and 820.10(b)(3)); and
a software release changed without documented design change control (820.10(c), ISO 13485 clause 7.3).
The observations are discussed at the closing meeting. Within 15 business days, the company sends one written response with a CAPA plan and evidence, including a review of related complaint records and earlier releases that were not cited. Our article on FDA adverse event reporting covers the reportability decision the first observation refers to.
FDA reviews the response together with the EIR and sends a classification letter. If a Warning Letter follows, the company responds, usually within 15 working days, and a close-out letter can only follow once FDA has verified the corrections. The classification and outcome are FDA's decisions, and the company cannot predict them.
Conclusion
A Form 483 and a Warning Letter sit at different points in the same process. The 483 records observations and invites a response; the Warning Letter records FDA's view that the violations are significant. The 15-business-day response to the 483 is where a firm has the most influence, and the response should cover the system behind each observation, not just the cited record.
Since February 2026, those observations are read through Part 820 and ISO 13485 together. If your quality records would not hold up to that reading, the time to fix them is before the inspection. Our audit team can support inspection readiness and 483 responses, and our overview of the ISO 13485 quality management system covers the underlying requirements. You can also contact MedQAIR.
Frequently asked questions
Is a Form 483 a Warning Letter?
No. A 483 lists inspectional observations at the end of an inspection and is not a final Agency determination. A Warning Letter is issued later, only for violations of regulatory significance.
Do I have to respond to a Form 483?
There is no legal requirement, but FDA encourages a written response with a corrective action plan. Responses received within 15 business days receive a detailed review before FDA decides whether to issue a Warning Letter.
Is the response window in business days or working days?
74 FR 40211 sets 15 business days for a 483 response. For a Warning Letter, RPM Chapter 4 states that FDA usually requests a response within 15 working days of receipt.
Can FDA take enforcement action without a Warning Letter?
Yes. RPM Chapter 4 states that a Warning Letter is not a prerequisite to taking enforcement action, and FDA may issue a Warning Letter at any time, independent of a 483 response.
What does OAI mean?
Official Action Indicated. In FDA's definition, it means the facility is in an unacceptable state of compliance. An inspection is classified OAI whenever a Warning Letter is issued.
How is a Warning Letter closed out?
For Warning Letters issued on or after 1 September 2009, FDA issues a close-out letter once the corrections have been made and verified, usually by a follow-up inspection. No close-out letter is issued for violations that are not correctable.
